Tumor Accumulation of Radiolabeled Bevacizumab due to Targeting of Cell- and Matrix-Associated VEGF-A Isoforms


Abstract

Purpose: Vascular endothelial growth factor-A (VEGF-A) is one of the most important factors inducing angiogenesis in tumors. Nine splice-variant isoforms of VEGF-A have been identified, each having different properties. Recently, we showed that radiolabeled anti-VEGF monoclonal antibody, bevacizumab, accumulates specifically in VEGF-A expressing tumors. In this study, we investigated in a nude mouse model which VEGF-isoforms are responsible for tumor accretion.

Materials and Methods: The humanized anti-VEGF-A antibody, A.4.6.1. (bevacizumab), was radiolabeled with In-111. The originally VEGF-negative Mel57 tumor was transfected with different VEGF isoforms (VEGF-121, VEGF-165, and VEGF-189). The obtained melanoma xenografts specifically expressing different VEGF-isoforms were used in mice. The bevacizumab uptake was examined in biodistribution studies and by gamma-camera imaging.

Results: The tumor cell line expressing VEGF-121 did not show specific uptake, most likely as a result of the fact that this isoform is freely diffusible. Tumors expressing VEGF-165 and -189 were clearly visualized by using gamma-camera imaging.

Conclusion: The accumulation of radiolabeled bevacizumab in the tumor is due to interaction with VEGF-A isoforms that are associated with the tumor cell surface and/or the extracellular matrix. Scintigraphic imaging of the expression of these VEGF isoforms may thus be useful to predict response to angiogenic therapy.

Key words: VEGF-A, isoforms, angiogenesis, bevacizumab, scintigraphy, Avastin

Introduction

Tumors cannot grow beyond a size of 1–2 mm³ unless new blood vessels are formed for oxygen and nutrient supply.1 Angiogenesis is a complex process that is regulated by the actions of pro- and antiangiogenic cytokines and hormones. Vascular endothelial growth factor-A (VEGF-A) is one of the most important proangiogenic growth factors. A well-characterized activity of VEGF-A is its ability to promote the growth and migration of vascular endothelial cells derived from arteries, veins, and even lymphatics.2 VEGF-A is the best-characterized member of the VEGF family and is thought to be the predominant and most critical regulator of the development of the vascular system in various tumors.3

The human VEGF-A gene is organized in nine exons, separated by eight introns4 and is localized on chromosome 6p21.3.5 Alternative splicing may result in the generation of six isoforms, having 121, 145, 165, 183, 189, and 206 amino acids, respectively, after signal-sequence cleavage. The amino acids encoded by exons 1–5 and 8 are contained in all isoforms. Exons 6 and 7 encode heparin-binding domains, which influence receptor binding and solubility. VEGF-189 and -206 contain a domain encoded by exon 6 and bind to heparin and heparan sulphate proteoglycans (HSPGs) with high affinity and are almost completely sequestered in the extracellular matrix (ECM). VEGF-165 is the most predominant isoform: It contains the exon 7–encoded domain, but lacks exon 6 and has intermediate properties; it is secreted, but a significant portion is bound to HSPGs on the cell surface and ECM.7 VEGF-121, which lacks both exons 6 and 7, does not bind to heparin and HSPGs and is, consequently, freely diffusible.8 We previously demonstrated, in a brain metastases
model, that VEGF-165 and -189 are angiogenic, whereas VEGF-121 mainly induced vasodilatation and vascular permeability. In clinical tumors, the 121 and 165 isoforms, and to a lesser extent, VEGF-A189, are the predominant VEGF isoforms.

Bevacizumab is a humanized variant of the anti-VEGF-A monoclonal antibody (mAb), A.4.6.1. It is directed against a common epitope encoded by exon 4 and expressed on all VEGF-A isoforms, preventing interaction with the tyrosine kinase receptors, VEGFR-1 and -2. It has been shown that antiangiogenic properties of bevacizumab result in growth inhibition of human tumors in nude mice. Bevacizumab was the first Food and Drug Administration–approved clinical agent to target tumor angiogenesis and has been registered in February 2004 for the first-line treatment of metastatic colorectal cancer in combination with Fluorouracil (5-FU)-based chemotherapy. In a recent report, the addition of bevacizumab to standard chemotherapy also produced a significant survival benefit in patients with advanced metastatic non-small-cell lung cancer, and it was approved for initial treatment of irresectable non-small-cell lung cancer in combination with carboplatin and paclitaxel in October 2006.

The marked variation in functional anatomy and pathophysiology within human tumors and within individual patients may account for the high variability of responses observed in patients. For example, in vessel-dense tissues such as the liver, tumors may profit from preexistent vasculature, thereby reducing the dependency on angiogenesis. Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia, as pointed out by Vermeulen et al. As a result, there is an urgent need for reliable markers that can predict which patients are most likely to respond to anti-VEGF therapy.

In a previous study, we showed that VEGF-A expression by the LS174T colon tumor xenografts could be visualized by gamma-camera imaging after the intravenous (i.v.) injection of In-111-labeled anti-VEGF mAb. VEGF-A expression in these xenografts was limited to the 121 and 165 amino-acid variants. However, it remains unclear which isoform(s) were visualized in these imaging experiments. The aim of this study was to determine which VEGF isoforms were actually targeted. Therefore, we analyzed bevacizumab uptake in melanoma xenografts in nude mice selectively expressing VEGF-121, -165, or -189.

Materials and Methods

Tumor model

All animal experiments were approved by the Animal Experiments Committee of the Radboud University Nijmegen Medical Center (Nijmegen, The Netherlands) and performed in accordance with their guidelines. Male nude BALB/c mice, 6–8 weeks old, were used after an acclimatization period of 2 weeks. The mice were housed (4 per cage) in a controlled environment with light-dark cycle conditions (12 hour light and 12h dark) and had free access to water and food. Stable transfectants of the Mel57 human melanoma cell line expressing VEGF-121, -165, or -189 were obtained, as described previously. Expression of proteins of the appropriate size in conditioned medium was confirmed by using Western blot, using anti-VEGF antibody A20 (Santa Cruz Biotechnology, Santa Cruz, CA).

Radiolabeling and quality control

For labeling with In-111, bevacizumab was conjugated with ethionocyanato-benzyl-DTPA (diethylene triamine pentaaetic acid), as described previously. Bevacizumab-DTPA (50 μg) was incubated with 20 MBq of In-111 in 0.15 M NaOH. The radiolabeled antibody preparations were purified by gel filtration on a PD-10 column (Amersham Biosciences, Roosendaal, The Netherlands) eluted with phosphate buffered saline (PBS) in 0.5% bovine serum albumin (BSA). The radiochemical purity (RCP) of the radiolabeled mAb (specific activity 0.3 MBq/μg) was determined by instant thin-layer chromatography (ITLC) and exceeded 97% for all preparations used in the studies.

VEGF-A levels in tumor xenografts

From the frozen melanoma xenografts expressing the different VEGF isoforms (VEGF-121, -165, and -189), thick cryosections were cut and pooled in RIPA buffer, (150 mM NaCl, 10 mM of Tris-HCl, pH 7.4, 1 mM of ethylene diamine tetraacetic acid, 1% NP-40, and 0.5% sodiumdeoxycholate) and a protease inhibitors cocktail (Roche, Basel, Switzerland) containing heparin (5 U/mL) to release matrix-bound isoforms of VEGF-A. Sections were homogenized, incubated on ice for 20 minutes, and centrifuged (800g for 20 minutes at 4°C) to prepare a clear lysate. Protein concentrations were determined by the Bradford method (Biorad, Hercules, CA), and VEGF-A concentrations were measured by enzyme linked immunosorobt assay (ELISA) as described previously. This ELISA detects all VEGF-isoforms.

Biodistribution and imaging experiments

Nude mice were injected subcutaneously (s.c.) in the left flank with 0.2 mL of Matrigel (Becton Dickinson, Franklin Lakes, NJ) containing 4x10⁵ Mel57-wt, Mel57-VEGF-121, Mel57-VEGF-165, or Mel57-VEGF-189 cells (n = 8 for each group). Approximately 14 days later, mice bearing 2–3 mm-diameter tumors (approximately 0.1 g) received an i.v. injection (via the tail vein) of 0.2 MBq of In-111-bevacizumab (0.2 mL). Three (3) mice from each group were co-injected with an excess of unlabeled bevacizumab (300 μg). Three (3) days after injection, mice were killed by CO₂ anesthesia and placed prone on a single-head gamma camera (Orbitor; Siemens, Hoffman Estates, IL) equipped with a parallel-hole medium-energy collimator. Images (100,000 counts/image)
were stored digitally in a 256×256 matrix. After the acquisition of the last images, mice were killed and tumors were snap-frozen for further analysis.

Results

VEGF-A levels in tumor xenografts

VEGF-A levels in tumor tissue extract were determined by using an ELISA assay. VEGF levels in the tumor extracts varied from 0.24 μg/g per tumor in the Mel57-wt xenograft to 4.03 μg/g per tumor in the Mel57-VEGF-165 xenograft. The VEGF levels in the Mel57-VEGF-121 and Mel57-VEGF-189 xenograft amounted to 0.64 and 1.13 μg/g per tumor, respectively. We found no correlation between the VEGF levels in the tumor xenografts and the specific accumulation of radiolabeled bevacizumab (Spearman correlation, 0.8; p < 0.20).

Biodistribution experiment

Expression of VEGF-A isoforms by the respective Mel57 transfectants is shown in Figure 1. The different transfectants exclusively produce the transfected isoform. The biodistribution of In-111-bevacizumab in mice with s.c. Mel57 tumors expressing different VEGF-A isoforms is summarized in Figure 2A–2D. Mel57 wild-type xenografts, known to express low levels of VEGF-A,22 showed an In-111-bevacizumab concentration of 8.6 ± 1.2 %ID/g. In the presence of an excess of unlabeled bevacizumab, the tumor uptake of the In-111-labeled antibody was reduced significantly: 3.9 ± 0.34 %ID/g, indicating that half of the antibody uptake was VEGF mediated. The concentration of In-111-bevacizumab in the Mel57-VEGF-121 tumor was 20 ± 3 %ID/g. Uptake in the Mel57-VEGF-121 tumors and normal tissues was not reduced in the presence of 300 μg of unlabeled antibody, indicating that In-111-bevacizumab accumulated only nonspecifically in these tumors. The concentration of In-111-bevacizumab in the Mel57-VEGF-189 tumor was 37 ± 13 %ID/g. Mel57-VEGF-165 tumors demonstrated an extremely high bevacizumab uptake of 64 ± 12 %ID/g, resulting in a tumor-to-blood ratio as high as 7.9 at 3 days postinjection. The concentration of In-111-bevacizumab in the Mel57-VEGF-165 and Mel57-VEGF-189 tumors decreased significantly upon the coinjection of an excess unlabeled antibody (20 and 4 %ID/g respectively), indicating that the major part of bevacizumab uptake in these tumors was specific (VEGF mediated).

Scintigraphic imaging

The images acquired at several time points after injection are shown in Figure 3. Immediately after injection (day 0), radioactivity was mainly present in the heart region and well-perfused organs. At day 3 post injection, activity had accumulated in the VEGF-165- and -189-positive tumors and had cleared from the circulation and nontarget organs, resulting in the distinct visualization of these tumors. Image quality further improved at day 7. The Mel57 wild-type tumors and the Mel57 tumors expressing VEGF-121 were not delineated in the images acquired 3 and 7 days postinjection, confirming the lack of specific accumulation of the antibody in these tumors.

Discussion

We and others recently demonstrated that radiolabeled bevacizumab specifically accumulates in VEGF-A-expressing tumors xenografted in nude mice.17,23 The In-111-labeled antibody allowed the detection of VEGF-A expression noninvasively by scintigraphic imaging. Bevacizumab is reported to have a high affinity for all VEGF-A isoforms, but it was unclear which isoforms expressed in the tumor were actually targeted and caused the specific accumulation in the tumor. Because previous work has shown that the larger isoforms of VEGF-A are more potent inducers of angiogenesis,9 it is important to know which VEGF-A isoform(s) are visualized during anti-VEGF imaging.

To determine which of the isoforms are responsible for the specific bevacizumab uptake, we used stable transfectants of the human melanoma cell line, Mel57, expressing each isoform in vitro at levels of 30–100 ng/mL per 10⁶ cells in 48 hours.9 The parental Mel57 cell line produces minimal amounts of VEGF-A in vitro.22 Consequently, Mel57 xenografts in nude mice grow to necrotic tumors, whereas VEGF-A-165 expression by these tumors results in a highly vascularized phenotype.24 In the present study, we demonstrate that only expression of the cell- or matrix-associated VEGF-A isoforms (VEGF-165 and -189) resulted in the tumor accumulation of radiolabeled bevacizumab.

The low levels of VEGF-A produced by the parental Mel57 xenografts were reflected in a very low specific uptake of bevacizumab. Specificity was assessed by the coinjection of an excess of unlabeled antibody. Highest tumor uptake was observed in the Mel57 tumor expressing VEGF-A-165 (64 ± 12 %ID/g). The Mel57-VEGF-189 tumor also showed a high and specific tumor uptake. This high antibody uptake most likely is due to the properties of VEGF-165 and -189: A significant portion remains bound to the cell surface and the extracellular
Interestingly, uptake in the Mel57-VEGF-121 tumors was not reduced when an excess of unlabeled antibody was coinjected, indicating that the antibody localized in these tumors nonspecifically. This can be explained by the fact that VEGF-121 is not retained in these tumors, resulting in the formation of soluble VEGF-antibody immune complexes that are not retained in the tumor.

In this study, major differences in nonspecific uptake of bevacizumab in the Mel57 variants were observed. The concentration of radiolabeled bevacizumab, when coinjecting an excess dose of unlabeled antibody, was relatively high in the tumors expressing the VEGF-isoforms, 121 and 165: 17.4 ± 2.23 and 19.6 ± 3.01 %ID/g, respectively. This may be the result of differences in blood volume, vascular permeability, and/or interstitial fluid pressure in the tumor xenografts, as VEGF-121 is reported to induce vasodilatation and to enhance vascular permeability. When grown in a brain metastasis model, Mel57 tumors that exclusively express VEGF-121 are characterized by a relative absence of intra-tumoral blood vessels, whereas highly dilated and hyper-permeable supposedly preexistent vessels are present in a peritumoral rim. VEGF-165 and -189 induce the formation of an intratumoral neovascular bed, consisting of irregularly dilated and leaky vessels. This is more prominent in VEGF-165-expressing tumors, when compared with VEGF-189 tumors. Thus, the enhanced nonspecific localization in the VEGF-121 and -165 tumors may be due to enhanced vascular permeability, which may cause enhanced extravasation of bevacizumab in this tumor. However, further studies are needed to make proof of this assumption. Such an experiment should measure the vascular permeability of the tumor xenograft transfected with VEGF-121.

The localization of radiolabeled bevacizumab in mice bearing s.c. xenografted human tumors expressing particular VEGF isoforms was also studied by scintigraphic imaging. The tumors expressing VEGF-165 and -189 were clearly visualized, whereas the tumors expressing the VEGF-121 isoform could not be delineated. VEGF-165 and -189 are extracellular matrix-bound proteins and are known to be most capable of inducing angiogenesis. Imaging these VEGF isoforms may, therefore, be useful in selecting patients who are likely to respond to antiangiogenic therapy.

However, part of the response to antiangiogenic therapy could be due to reducing the interstitial fluid pressure in the tumor. VEGF-121 may not be the main isoform responsible for angiogenesis, but this isoform is well capable of inducing vasodilatation and enhancing vascular permeability. This results in inefficient blood flow and high interstitial fluid...
pressure in the tumor, which leads to decreased uptake of drugs or other therapeutics in tumors. Combining anti-VEGF-therapy with chemotherapy has resulted in an anti-tumor effect, presumably by the normalization of the tumor vasculature, partly as a result of blocking the effect of VEGF-121. As described above, the tumors expressing the VEGF-121 isoform could not be delineated.

Conclusions

This study is the first to demonstrate the specific tumor localization of radiolabeled bevacizumab in xenografted human tumors expressing particular VEGF isoforms. Tumors expressing only VEGF-121 showed no specific uptake of radiolabeled bevacizumab, most likely as a result of the fact that this isoform is freely diffusible and is not retained in the tumor. Mel57-VEGF-165 and Mel57-VEGF-189 demonstrated relatively high, specific tumor uptake of the labeled antibody. Thus, scintigraphy with radiolabeled bevacizumab appears to allow in vivo visualization of the VEGF-A isoforms that are most capable of inducing angiogenesis and may thus be useful to predict response to antiangiogenic therapy. However, it should be noted that tumors with predominantly VEGF-121 expression will not be visualized, whereas such tumors might still be susceptible to avastin-induced vessel normalization.
Disclosure Statement

No competing financial conflicts exist.

References

This article has been cited by:


